Targene focused on tissue targeting adeno-associated virus (AAV) and customed targeting plasmid research and development with a starting of cartilage targeting AAV. Our short-term objectives are scientific study service and license out based on our current products. We also aimed at exploring the potential application of tissue targeting AAV in gene therapy by pre-clinical and clinical trials as our long period objectives. Targene aims to provide tissue targeting recombinant AAV to solve the lack of targeting from the wild type AAV. Our current customers are bone and joint laboratories in Hong Kong, China mainland and overseas. We also provide license out service to other friendly companies to broaden our market. And by collaborating with clinicians, our future potential customers will be certain patients that need gene therapy. 拓進生物科技專注於組織靶向腺相關病毒(tissue targeting adeno-associated virus, AAV)和靶向序列質粒的研究、開發與訂製，以軟骨靶向AAV為起點。我們的短期目標是在現有產品的基礎上提供科學的研究服務和授權，並幫助客戶開發新型AAV。我們的長期目標是通過臨床前和臨床試驗探索組織靶向AAV在基因治療中的潛在應用。拓進生物科技旨在提供組織靶向重組AAV，解決野生型AAV缺乏靶向的問題。我們目前的客戶是香港、中國大陸和海外的骨骼和關節病實驗室。我們也為其他友商提供許可服務，以擴大我們的市場。通過與臨床醫生的合作，我們未來的潛在客戶將是某些需要基因治療的病人。

2020

Biotech

TSSSU Company